Investigational drug · Phase 2
CAL02
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pneumonia, Bacterial.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CAL02"
First trial start
2023
Jul 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAL02", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumonia, Bacterial
Approved drugs for the same conditions: Pneumonia · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "CAL02" as an intervention, largest first.
- Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial PneumoniaPivotal-lookingActive, not recruiting
Eagle Pharmaceuticals, Inc.Industry
NCT05776004 · 276 participants (planned) · Start Jul 22, 2023 · Primary completion Feb 10, 2026
Drug: CAL02; Placebo · For: Pneumonia, Bacterial
Sites: Fresno, California; Gainesville, Florida; Chicago, Illinois · 90 sites in all
Combioxin SAIndustry
NCT02583373 · 19 participants · Start Mar 21, 2016 · Primary completion Feb 20, 2018
Drug: CAL02 Low-dose; CAL02 High-dose and 1 more · For: Pneumonia; Pneumococcal Infections
Sites: Brussels, Belgium; Ottignies, Belgium; Besançon, France · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A soft anti-virulence liposome realizing the explosive release of antibiotics at an infectious site to improve antimicrobial therapy.
Zhang S, Lu X, Wang B, et al. · J Mater Chem B 2021
- Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence.
Sellarès-Nadal J, Burgos J, Falcó V, et al. · J Exp Pharmacol 2020
- Antimicrobial lipids in nano-carriers for antibacterial delivery.
Zhang Q, Wu W, Zhang J, et al. · J Drug Target 2020
- Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections-A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug.
Azeredo da Silveira S, Shorr AF · Antibiotics (Basel) 2020
- CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF, Colin G, Dequin PF, et al. · Lancet Infect Dis 2019
Also in development for Pneumonia, Bacterial
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.